文献速递神经核医学

年龄与性别校正对多巴胺转运体SPECT诊断效能的影响

Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-10-31

本研究在三个独立患者样本中检验年龄与性别校正对壳核SBR诊断帕金森综合征效能的影响。结果显示校正后AUC在PPMI样本略降(0.9955 vs 0.9969,p=0.025),临床样本A略降(0.9448 vs 0.9519,p=0.057),临床样本B略升但无统计学意义(0.9828 vs 0.9743,p=0.232)。结论不支持在帕金森综合征诊断流程中对壳核FP-CIT SBR进行年龄与性别校正。

要点

  • 壳核SBR随年龄下降约3.3–10.4%,女性高于男性(PPMI 14%,样本A 7%,样本B 6%)。
  • 年龄与性别校正后AUC在PPMI样本显著略降,在临床样本A接近显著略降,样本B无显著变化。
  • 年龄与性别所致个体间方差占比远低于神经退行性帕金森综合征约50%的SBR降低阈值。

核心结论

  • 研究结果不支持在帕金森综合征诊断流程中对壳核FP-CIT SBR进行年龄与性别校正。
  • 原因可能是年龄与性别引起的个体间方差比例远低于神经退行性帕金森综合征约50%的SBR降低阈值。

研究设计与样本

  • 研究样本:207例健康对照(HC)和438例帕金森病(PD)患者。
  • 临床样本A:来自一个中心的183例神经退行性帕金森综合征(PS)患者和183例非神经退行性PS患者。
  • 临床样本B:来自另一个中心的84例神经退行性PS患者和38例非神经退行性PS患者。
  • 年龄与性别校正基于HC或非神经退行性PS的线性回归,在各样本中分别进行;以ROC曲线下面积(AUC)为效能指标。

主要发现

  • 女性壳核SBR高于男性:PPMI样本高14%(p<0.0005),临床样本A高7%(p<0.0005),临床样本B高6%(p=0.361)。
  • 壳核SBR随年龄下降幅度在3.3%至10.4%之间(p≤0.019)。
  • 在≥50岁受试者中,年龄与性别解释的SBR个体间方差不足10%。
  • 校正后AUC:PPMI样本0.9955 vs 0.9969(p=0.025),临床样本A 0.9448 vs 0.9519(p=0.057),临床样本B 0.9828 vs 0.9743(p=0.232)。

关键数值与推荐

  • 壳核SBR年龄相关下降约每十年5%,女性约高10%(原文引言背景)。
  • 神经退行性帕金森综合征的SBR降低阈值约为50%。

临床怎么用

  • 在帕金森综合征的FP-CIT SPECT诊断判读中,无需对壳核SBR常规进行年龄与性别校正。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The specific binding ratio (SBR) of 123I-FP-CIT (FP-CIT) in the putamen decreases with age by about 5% per decade and most likely is about 10% higher in females. However, the clinical utility of age and sex correction of the SBR is still a matter of debate. This study tested the impact of age and sex correction on the diagnostic performance of the putamen SBR in three independent patient samples. METHODS: Research sample: 207 healthy controls (HC) and 438 Parkinson's disease (PD) patients. Clinical sample A: 183 patients with neurodegenerative parkinsonian syndrome (PS) and 183 patients with non-neurodegenerative PS from one site. Clinical sample B: 84 patients with neurodegenerative PS and 38 patients with non-neurodegenerative PS from another site. Correction for age and sex of the putamen SBR was based on linear regression in the HC or non-neurodegenerative PS, separately in each sample. The area under the ROC curve (AUC) was used as performance measure. RESULTS: The putamen SBR was higher in females compared to males (PPMI: 14%, p < 0.0005; clinical sample A: 7%, p < 0.0005; clinical sample B: 6%, p = 0.361). Age-related decline of the putamen SBR ranged between 3.3 and 10.4% (p ≤ 0.019). In subjects ≥ 50 years, age and sex explained < 10% of SBR between-subjects variance. Correction of the putamen SBR for age and sex resulted in slightly decreased AUC in the PPMI sample (0.9955 versus 0.9969, p = 0.025) and in clinical sample A (0.9448 versus 0.9519, p = 0.057). There was a small, non-significant AUC increase in clinical sample B (0.9828 versus 0.9743, p = 0.232). CONCLUSION: These findings do not support age and sex correction of the putaminal FP-CIT SBR in the diagnostic workup of parkinsonian syndromes. This most likely is explained by the fact that the proportion of between-subjects variance caused by age and sex is considerably below the symptom threshold of about 50% reduction in neurodegenerative PS.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Schmitz-Steinkrüger H, Lange C, Apostolova I, et al. Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT. Eur J Nucl Med Mol Imaging. 2020. PMID: 33130960. doi:10.1007/s00259-020-05085-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。